HUMANIGEN
Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.
HUMANIGEN
Industry:
Biopharma Biotechnology Health Care Pharmaceutical
Founded:
2001-01-01
Address:
Burlingame, California, United States
Country:
United States
Website Url:
http://www.humanigen.com
Total Employee:
1+
Status:
Active
Contact:
650-243-3100
Total Funding:
369.45 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Content Delivery Network Google Universal Analytics Euro
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Verastem Oncology
Verastem is a biopharmaceutical company that focuses on discovering and developing novel drugs that selectively target cancer stem cells.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
Current Employees Featured
Cameron Durrant Chairman, CEO and Interim CFO @ Humanigen
Chairman, CEO and Interim CFO
Geoffrey Yarranton Chief Scientific Officer and Executive Vice President of Research and Development @ Humanigen
Chief Scientific Officer and Executive Vice President of Research and Development
2006-10-01
Jeffrey H. Cooper Chief Financial Officer @ Humanigen
Chief Financial Officer
Morgan Lam Chief Scientific Officer @ Humanigen
Chief Scientific Officer
David W. Pritchard President and Chief Executive Officer, Board of Directors @ Humanigen
President and Chief Executive Officer, Board of Directors
2006-08-01
Nestor A. Molfino Chief Medical Officer @ Humanigen
Chief Medical Officer
2012-05-01
Donald R. Joseph Chief Legal Officer @ Humanigen
Chief Legal Officer
2013-06-01
Herb C. Cross Chief Financial Officer @ Humanigen
Chief Financial Officer
2013-10-01
Jeanne Y. Jew Head of Business Development @ Humanigen
Head of Business Development
2008-04-01
Ken Trbovich SVP of Investor Relations @ Humanigen
SVP of Investor Relations
2021-06-01
Founder
Stock Details
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Humanigen
Cheval Holdings
Cheval Holdings investment in Post-IPO Equity - Humanigen
Nomis Bay
Nomis Bay investment in Post-IPO Equity - Humanigen
Black Horse Capital Advisors
Black Horse Capital Advisors investment in Post-IPO Equity - Humanigen
Fidelity
Fidelity investment in Private Equity Round - Humanigen
Alloy Ventures
Alloy Ventures investment in Series D - Humanigen
Mitsubishi UFJ Capital
Mitsubishi UFJ Capital investment in Series D - Humanigen
Sofinnova Investments
Sofinnova Investments investment in Series D - Humanigen
5AM Ventures
5AM Ventures investment in Series D - Humanigen
GBS Ventures
GBS Ventures investment in Series D - Humanigen
Key Employee Changes
Date | New article |
---|---|
2021-06-07 | Humanigen Announces Ken Trbovich Appointed as Senior Vice President, Investor Relations |
Official Site Inspections
http://www.humanigen.com Semrush global rank: 1.13 M Semrush visits lastest month: 28.57 K
- Host name: 147.62.236.23.bc.googleusercontent.com
- IP address: 23.236.62.147
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
